Sun Pharmaceutical Industries has informed that the postal ballot process initiated pursuant to the notice dated 17 March 2026, wherein the voting period commenced on 19 March 2026, has been concluded today, 17 April 2026. Based on the Scrutinizer’s Report, the following resolutions as set out in the Postal Ballot Notice dated 17 March 2026 have been duly passed by the shareholders with the requisite majority and shall be deemed passed on 17 April 2026 to take effect in accordance with applicable regulatory requirements and subject to completion of statutory filings and compliance. Ratification of the remuneration of the Cost Auditor for FY 2025–26; Alteration to Clause III(A) (Main Objects) of the Memorandum of Association; and 3. Re-appointment of Dr Pawan Goenka as an Independent Director for a second term of five years, effective from 21 May 2026. The Voting Results have been filed by the Company in XBRL mode, and the Scrutinizer Report is made available on the Company’s website at www.sunpharma.com.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: